Over 1,000 patients with Alzheimer’s are now enrolled in Phase 3 studies.

Expect to reach enrollment target of approximately 1,750 patients for the Phase 3 studies by year-end 2023.

Top-line results for an open-label study showed Simufilam was well-tolerated, with 47% of patients improving on ADAS-Cog scores over 12 months and an additional 23% declining less than 5 points on ADAS-Cog.

Cassava Sciences is currently evaluating simufilam tablets for Alzheimer’s disease dementia in two Phase 3 clinical studies.